ResearcherSapienza University of RomeActive in the last 2 years

Erika Testa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0101-2973; OpenAlex author ID A5030336076. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2026: 1 paper

Papers 1

Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.2601788123 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Carlo M Croce · 1 shared paper, 2026 · strength 0.23
- Paper Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma. DOI 10.1073/pnas.2601788123 ↗
Vincenzo Corbo · 1 shared paper, 2026 · strength 0.23
- Paper Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma. DOI 10.1073/pnas.2601788123 ↗
Geny Piro · 1 shared paper, 2026 · strength 0.23
- Paper Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma. DOI 10.1073/pnas.2601788123 ↗
Gian Luca Rampioni Vinciguerra · 1 shared paper, 2026 · strength 0.23
- Paper Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma. DOI 10.1073/pnas.2601788123 ↗
Carmine Carbone · 1 shared paper, 2026 · strength 0.23
- Paper Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma. DOI 10.1073/pnas.2601788123 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.